NCT02467647Unknown1 期
Phase 1 Study of the Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy
Wuhan University1 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2015年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 500
- 试验地点
- 1
- 主要终点
- Overall survival of patients with multiple myeloma treated with Huang-Lian-Jie-Du-Tang（HLJDT) in maintain therapy
研究概览
简要总结
To investigate the efficacy of the combination of Thalidomide and Huang-Lian-Jie-Du-Tang on the patients with multiple myeloma in maintain therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 20 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients can take HLJDT
排除标准
- •patients can not take HLJDT
研究组 & 干预措施
A
Experimental
Arm A: HLJDT 150ml three times per day for 6 months and Thalidomide 100mg once per day for 6 months
干预措施: Thalidomide (Drug)
A
Experimental
Arm A: HLJDT 150ml three times per day for 6 months and Thalidomide 100mg once per day for 6 months
干预措施: HLJDT (Drug)
B
Active Comparator
Arm B: Thalidomide 100mg oral once per day for 6 months
干预措施: Thalidomide (Drug)
结局指标
主要结局
Overall survival of patients with multiple myeloma treated with Huang-Lian-Jie-Du-Tang（HLJDT) in maintain therapy
时间窗: 6 months
次要结局
未报告次要终点
研究者
Shangqin Liu
Professor
Wuhan University
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma RecurrenceAdult Hepatocellular CarcinomaRecurrent Hepatocellular CarcinomaAdverse Reaction to DrugVascular Endothelial Growth Factor OverexpressionNCT02447679Chang Gung Memorial Hospital40
已完成
2 期
Thalidomide in Combination With Temodar in Patients With Neuroendocrine TumorsNeuroendocrine TumorNCT00165230Dana-Farber Cancer Institute32
尚未招募
2 期
Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver CancerLiver CancerNCT06408623Cancer Institute and Hospital, Chinese Academy of Medical Sciences48
Unknown
2 期
Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MMMultiple MyelomaNCT03605056Peng Liu25
已完成
2 期
Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple MyelomaMultiple MyelomaNCT00538733Weill Medical College of Cornell University26